Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models

BACKGROUND: Non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14) occurs in 3-4% of NSCLC cases and defines a subset of patients with distinct characteristics. While MET targeted therapy has led to strong clinical results in METex14 patients, acquired drug resistance seemed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yunhua, Gu, Linping, Li, Yingqi, Zhao, Ruiying, Jian, Hong, Xie, Wenhui, Liu, Liu, Wu, Huiwen, Ren, Fang, Han, Yuchen, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634635/
https://www.ncbi.nlm.nih.gov/pubmed/36338758
http://dx.doi.org/10.3389/fonc.2022.1024818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634635/
https://www.ncbi.nlm.nih.gov/pubmed/36338758
http://dx.doi.org/10.3389/fonc.2022.1024818

Ejemplares similares